Priority actions for elevating liver health in Canada: A call to action.

Chronic liver disease (CLD) has become a silent epidemic in our country and has resulted in significant physical, psychosocial, and financial burden. Although other international liver associations have published frameworks for the principal actions required to improve liver health across health systems, Canada does not have a strategy to address the growing concerns of CLD. Thus, a multidisciplinary group of care providers involved in CLD management in Canada gathered to review the current burden of disease, gaps in management, and key opportunities for improving the identification and management of people at risk of developing progressive CLD.

Informations de copyright

© Canadian Association for the Study of the Liver, 2023.

Déclaration de conflit d'intérêts

M Brahmania has speaking, ad board, and/or research funding from Roche, Eisai, Merck, and AbbVie; MJ Biondi has received clinical consulting fees from Omega Specialty Nurses and McKesson Canada, as well as speaking, ad board, and/or research funding from Abbott, 
AbbVie, and Gilead; S Joshi has received speaking and advisory board consulting fees from Abbvie and Gilead; H-M Jung has received clinical consulting fees from Roche; M Kehar has received clinical consulting fees from Roche; E Lee has received speaking and advisory fees from AbbVie and Gilead.